Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 11/20 | 0.56 |
| ▸ | BRD9 | Q9H8M2 | 6/20 | 0.56 |
| ▸ | BPTF | Q12830 | 8/20 | 0.53 |
| ▸ | BRD4 | O60885 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.43 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.43 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964987 | 0.78 | KAT2B (0.41) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL979278 | 0.78 | KAT2B (0.60) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL31735389 | 0.77 | BRD9 (0.42) | KAT2BBRD9BPTFBRD4BRD7 | |
| SCHEMBL14074017 | 0.77 | KAT2B (0.58) | KAT2BBRD9BPTFBRD4MAPT | |
| Hydrochloric Acid SCHEMBL17912386 | 0.77 | KAT2B (0.58) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL11689631 | 0.75 | KAT2B (0.35) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL4163687 | 0.75 | KAT2B (0.47) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL23318253 | 0.75 | KAT2B (0.43) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL23755064 | 0.75 | KAT2B (0.56) | KAT2BBRD9BPTFBRD4MAPT | |
| SCHEMBL17912364 | 0.75 | KAT2B (0.56) | KAT2BBRD9BPTFBRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-0733633-B1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-5753664-A | ANTITUMOR AGENTS, PYRIMIDONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0733633-A1 | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | KAT2B 3751/4885BRD9 2138/4885BPTF 3293/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | KAT2B 3315/4885BRD9 946/4885BPTF 2192/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | KAT2B 3242/4885BRD9 2623/4885BPTF 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.